Income statement
USD
Annual
| Metric | 2010 | 2009 | 2008 |
|---|---|---|---|
| Revenue | 32M | 23M | 16M |
| Gross Profit | 16M | 12M | 8M |
| Operating Income | 13M | 9M | 6M |
| EBITDA | 14M | 10M | 7M |
| Net Income | 13M | 9M | 6M |
| EPS (Diluted) | — | — | — |
Healthcare
Live Price
Offline$0.0001
+0.00% today
Window Change
+0.00%
Window
Jun 23, 2025 → Dec 30, 2025
Historical coverage is still expanding
This 1Y daily history view is usable, but not fully loaded yet. Additional bars will appear as backfills continue.
Coverage: 133 bars · Jun 23, 2025 → Dec 30, 2025
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Tibet Pharmaceuticals, Inc. (TBET) is a Healthcare stock with a market cap of $1.49K and listed on OTC. The stock last traded around $0.00 and up 0.0% across the available one-year price window (Jun 23, 2025 → Dec 30, 2025). Baseline metrics include revenue growth of +40.7%, EPS growth of +40.5%, a dividend yield of 0.0%. What stands out right now is revenue +40.7%, EPS +40.5%, free cash flow -25.4% with operating margin 41.1% and ROIC 0.0%. Valuation is more restrained than many high-expectation growth names at P/E 0.0 and price/sales 0.0. Stock Foundry combines TBET price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TBET
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
TBET Max Drawdown
0.00%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for TBET and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$15.6M
-32.3% YoY
FY Net Income
$5.9M
-35.8% YoY
Free Cash Flow
$5.5M
-46.3% YoY
Revenue Growth
+40.7%
EPS Growth
+40.5%
Gross Margin
50.0%
Net Margin
40.6%
Income statement
USD
| Metric | 2010 | 2009 | 2008 |
|---|---|---|---|
| Revenue | 32M | 23M | 16M |
| Gross Profit | 16M | 12M | 8M |
| Operating Income | 13M | 9M | 6M |
| EBITDA | 14M | 10M | 7M |
| Net Income | 13M | 9M | 6M |
| EPS (Diluted) | — | — | — |
Balance sheet
USD
| Metric | 2010 | 2009 | 2008 |
|---|---|---|---|
| Cash & Equivalents | 8M | 4M | 3M |
| Total Assets | 28M | 18M | 16M |
| Total Liabilities | 5M | 7M | 6M |
| Shareholder Equity | 23M | 11M | 10M |
| Total Debt | 0 | 4M | 4M |
| Net Debt | -8M | -500K | 858K |
Cash flow positioning
Latest Full Year
Operating Cash Flow
6M
-40.1% YoY
Capital Expenditures
642K
Free Cash Flow
6M
-46.3% YoY
Key ratios
Gross Margin
50.0%
Operating Margin
41.1%
Net Margin
40.6%
ROE
77.3%
Debt / Equity
0.00x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.